SUPLATAST TOSILATE

Details

Stereochemistry	RACEMIC
Molecular Formula	C16H26NO4S.C7H7O3S
Molecular Weight	499.641
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1=CC=C(C=C1)S([O-])(=O)=O.CCOCC(O)COC2=CC=C(NC(=O)CC[S+](C)C)C=C2

InChI

InChIKey=RYVJQEZJUFRANT-UHFFFAOYSA-N

InChI=1S/C16H25NO4S.C7H8O3S/c1-4-20-11-14(18)12-21-15-7-5-13(6-8-15)17-16(19)9-10-22(2)3;1-6-2-4-7(5-3-6)11(8,9)10/h5-8,14,18H,4,9-12H2,1-3H3;2-5H,1H3,(H,8,9,10)

HIDE SMILES / InChI

Molecular Formula	C16H26NO4S
Molecular Weight	328.447
Charge	1
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Molecular Formula	C7H7O3S
Molecular Weight	171.194
Charge	-1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.astellas.com/en/corporate/news/yamanouchi/030123.html
Curator's Comment: Description was created based on several sources, including https://www.jstage.jst.go.jp/article/allergolint/54/4/54_4_533/_pdf

Suplatast is a novel immunomodulator that can adjust the imbalance in the Th1/Th2 immune response and shows clear clinical efficacy against bronchial asthma (BA). Suplatast tosilate helps to suppress the production of IgE, to block the production of cytokines and to suppress allergy-related eosinophils. Clinical studies on the efficacy of Suplatast were carried out in Japan. Suplatast showed adequate efficacy for the treatment of BA, allergic rhinitis and atopic dermatitis. Suplatast is now available for the management of BA as a controller of the Th2-dependent allergic inflammation. Suplatast tosilate is not approved in the United States, but is available in Japan as Tosilart® and IPD Capsules®. IPD-1151T (suplatast tosilate) was originated by Taiho and is being developed for the treatment of interstitial cystitis and chronic non-bacterial prostatitis as additional indications. IPD-1151T treatment for 1 year resulted in a significantly increased bladder capacity and decreased symptoms, such as urinary urgency, frequency and lower abdominal pain, in patients with nonulcerative interstitial cystitis.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Interleukin-4 2 Target ID: P05112 Gene ID: 3565.0 Gene Symbol: IL4 Target Organism: Homo sapiens (Human) Sources: http://www.ncbi.nlm.nih.gov/pubmed/10466742	Inhibitor 8297
Interleukin-5 3 Target ID: CHEMBL1169600 Sources: http://www.ncbi.nlm.nih.gov/pubmed/10466742	Inhibitor 8297
Histidine decarboxylase 9 Target ID: CHEMBL3243911 Sources: http://www.ncbi.nlm.nih.gov/pubmed/19596986	Inhibitor 8297

Conditions

Condition	Modality	Highest Phase	Product
Cutaneous mastocytosis 2 Sources: http://www.ncbi.nlm.nih.gov/pubmed/25779849	Primary	Basic research	Unknown Approved Use Unknown
Eosinophilic cystitis 2 Sources: http://www.ncbi.nlm.nih.gov/pubmed/25293800	Primary	Basic research	Unknown Approved Use Unknown
Non-episodic angioedema 2 Sources: http://www.ncbi.nlm.nih.gov/pubmed/24723649	Primary	Basic research	Unknown Approved Use Unknown
Bronchial asthma 50 Sources: https://www.jstage.jst.go.jp/article/allergolint/54/4/54_4_533/_pdf	Primary	Phase III 656	Unknown Approved Use Unknown
Kimura's disease 2 Sources: http://www.ncbi.nlm.nih.gov/pubmed/21914581	Primary	Basic research	Unknown Approved Use Unknown
Interstitial cystitis 6 Sources: http://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-060257	Primary	Phase III 656	Unknown Approved Use Unknown
Perennial allergic rhinitis 47 Sources: http://www.ncbi.nlm.nih.gov/pubmed/9879412	Primary	Basic research	Unknown Approved Use Unknown
Bronchial asthma 50 Sources: http://www.ncbi.nlm.nih.gov/pubmed/24561769	Preventing	Phase II 1132	Unknown Approved Use Unknown
Vitiligo 9 Sources: http://www.ncbi.nlm.nih.gov/pubmed/9609984	Primary	Basic research	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Suplatast tosilate affects the initial increase in specific IgE and interleukin-4 during immunotherapy for perennial allergic rhinitis.	1998	9879412
Suplatast tosilate (IPD), a new immunoregulator, is effective in vitiligo treatment.	1998 Apr	9609984
Suplatast tosilate inhibits goblet-cell metaplasia of airway epithelium in sensitized mice.	2000 Apr	10756224
Kimura's disease treated with suplatast tosilate and loratadine.	2011 Nov-Dec	21914581
Treatment of non-episodic angioedema associated with eosinophilia with suplatast tosilate, an anti-allergic selective Th2 cytokine inhibitor.	2014 Mar-Apr	24723649
Suplatast tosilate for treating cutaneous mastocytosis.	2015 May-Jun	25779849

Patents

Sample Use Guides

In Vivo Use Guide

IPD-1151T (suplatast tosilate) 100 mg capsules was orally administered to the patients 3 times daily for 12 weeks of treatment period.

Route of Administration: Oral

In Vitro Use Guide

In vitro, NCI-H292 cells were preincubated with suplatast tosilate (0.1-100 u/mL) 1 hour.

Substance Class	Chemical Created by `admin` on `Sat Dec 16 06:45:09 UTC 2023` Edited by `admin` on `Sat Dec 16 06:45:09 UTC 2023`
Record UNII	C9J89787U1
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

SUPLATAST TOSILATE

Official Name

English

SUPLATAST TOSYLATE

Common Name

English

Suplatast tosilate [WHO-DD]

Common Name

English

IPD

Brand Name

English

suplatast tosilate [INN]

Common Name

English

SUPLATAST TOSILATE [MART.]

Common Name

English

SUPLATAST TOSYLATE [MI]

Common Name

English

SULFONIUM, (3-((4-(3-ETHOXY-2-HYDROXYPROPOXY)PHENYL)AMINO)-3-OXOPROPYL)DIMETHYL-, SALT WITH 4-METHYLBENZENESULFONIC ACID (1:1)

Common Name

English

SUPLATAST TOSILATE [JAN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C574